Use of in vivo-induced antigen technology for identification of Escherichia coli O157:H7 proteins expressed during human infection

Manohar John, Indira T. Kudva, Robert W. Griffin, Allen W. Dodson, Bethany McManus, Bryan Krastins, David Sarracino, Ann Progulske-Fox, Jeffrey D. Hillman, Martin Handfield, Phillip I. Tarr, Stephen B. Calderwood

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Abstract

Using in vivo-induced antigen technology (IVIAT), a modified immunoscreening technique that circumvents the need for animal models, we directly identified immunogenic Escherichia coli O157:H7 (O157) proteins expressed either specifically during human infection but not during growth under standard laboratory conditions or at significantly higher levels in vivo than in vitro. IVIAT identified 223 O157 proteins expressed during human infection, several of which were unique to this study. These in vivo-induced (ivi) proteins, encoded by ivi genes, mapped to the backbone, O islands (OIs), and pO157. Lack of in vitro expression of O157-specific ivi proteins was confirmed by proteomic analysis of a mid-exponential-phase culture of E. coli O157 grown in LB broth. Because ivi proteins are expressed in response to specific cues during infection and might help pathogens adapt to and counter hostile in vivo environments, those identified in this study are potential targets for drug and vaccine development. Also, such proteins may be exploited as markers of O157 infection in stool specimens.

Original languageEnglish
Pages (from-to)2665-2679
Number of pages15
JournalInfection and immunity
Volume73
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Dive into the research topics of 'Use of in vivo-induced antigen technology for identification of Escherichia coli O157:H7 proteins expressed during human infection'. Together they form a unique fingerprint.

Cite this